Introducing a specialist drug Kardex can significantly change prescribing practices for VTE in cancer patients

Hdl Handle:
http://hdl.handle.net/10147/323319
Title:
Introducing a specialist drug Kardex can significantly change prescribing practices for VTE in cancer patients
Authors:
Coleman, N; Young, R; Greally, M; O Riordan, L; Breathnach, O; Grogan, L
Citation:
Coleman N et al. Introducing a specialist drug Kardex can significantly change prescribing practices for VTE in cancer patients. IMJ 2014 Jun 107(6)
Publisher:
Irish Medical Journal
Issue Date:
Jun-2014
URI:
http://hdl.handle.net/10147/323319
Abstract:
We read with interest the results of the ENDORSE Study 1 . This study clearly demonstrated a high prevalence of risk for venous thromboembolism (VTE) and a low rate of prophylaxis use, particularly in medical patients. Of those at-risk medical and surgical patients with no contraindication to VTE prophylaxis, overall 57% received recommended VTE prophylaxis, with 64% surgical and 47% medical patients, receiving the recommended prophylaxis, respectively. We note that with regard to risk factors present prior to admission, active malignancy was an issue in only 6.7% (n=19) of the patients included in the study, and as inpatients only 2 patients (0.7%) underwent cancer therapy. As such, cancer patients are perhaps underrepresented in this cohort. Cancer is a well-known risk factor for the development of VTE, and VTE is a common and life-threatening condition in cancer patients, resulting in a shorter life expectancy than either cancer patients without VTE or noncancer patients with VTE 2,3 . Effective thromboprophylaxis reduces the risk for VTE and improves outcomes.
Item Type:
Article; Other
Language:
en
Keywords:
CANCER; PRESCRIBING

Full metadata record

DC FieldValue Language
dc.contributor.authorColeman, Nen_GB
dc.contributor.authorYoung, Ren_GB
dc.contributor.authorGreally, Men_GB
dc.contributor.authorO Riordan, Len_GB
dc.contributor.authorBreathnach, Oen_GB
dc.contributor.authorGrogan, Len_GB
dc.date.accessioned2014-07-17T12:00:43Z-
dc.date.available2014-07-17T12:00:43Z-
dc.date.issued2014-06-
dc.identifier.citationColeman N et al. Introducing a specialist drug Kardex can significantly change prescribing practices for VTE in cancer patients. IMJ 2014 Jun 107(6)en_GB
dc.identifier.urihttp://hdl.handle.net/10147/323319-
dc.description.abstractWe read with interest the results of the ENDORSE Study 1 . This study clearly demonstrated a high prevalence of risk for venous thromboembolism (VTE) and a low rate of prophylaxis use, particularly in medical patients. Of those at-risk medical and surgical patients with no contraindication to VTE prophylaxis, overall 57% received recommended VTE prophylaxis, with 64% surgical and 47% medical patients, receiving the recommended prophylaxis, respectively. We note that with regard to risk factors present prior to admission, active malignancy was an issue in only 6.7% (n=19) of the patients included in the study, and as inpatients only 2 patients (0.7%) underwent cancer therapy. As such, cancer patients are perhaps underrepresented in this cohort. Cancer is a well-known risk factor for the development of VTE, and VTE is a common and life-threatening condition in cancer patients, resulting in a shorter life expectancy than either cancer patients without VTE or noncancer patients with VTE 2,3 . Effective thromboprophylaxis reduces the risk for VTE and improves outcomes.en_GB
dc.languageen-
dc.language.isoenen
dc.publisherIrish Medical Journalen_GB
dc.subjectCANCERen_GB
dc.subjectPRESCRIBINGen_GB
dc.titleIntroducing a specialist drug Kardex can significantly change prescribing practices for VTE in cancer patientsen_GB
dc.typeArticleen
dc.typeOtheren
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.